Verducatib

Verducatib is an investigational new drug that is being evaluated by Boehringer Ingelheim for the treatment of bronchiectasis. It is a cathepsin C inhibitor.
Wikipedia contributors, "Verducatib", Wikipedia, revision 1384999309, retrieved 20 November 2026, source, CC BY-SA 4.0.